MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 2 | 1.0 |
Embryo Transfer/*standards | 2 | 1.0 |
Female | 282 | 0.0 |
Humans | 465 | 0.0 |
Meta-Analysis | 3 | 1.0 |
Pregnancy | 12 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Pregnancy Rate | 2 | 1.0 |
Pregnancy, Multiple | 2 | 1.0 |
Randomized Controlled Trials | 3 | 0.0 |
Review Literature | 2 | 1.0 |
Aged | 80 | 0.0 |
Aged, 80 and over | 20 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Tumor Cells, Cultured | 24 | 0.0 |
Acromegaly/diagnosis/*etiology | 3 | 100.0 |
Magnetic Resonance Imaging | 9 | 0.0 |
Middle Aged | 112 | 0.0 |
Pituitary Gland/pathology | 2 | 8.0 |
Somatotropin-Releasing Hormone/*secretion | 9 | 90.0 |
Treatment Outcome | 2 | 0.0 |
Arginine/pharmacology | 7 | 25.0 |
*Body Height | 9 | 21.0 |
Child | 96 | 0.0 |
Male | 337 | 0.0 |
Reference Values | 34 | 0.0 |
Research Support, Non-U.S. Gov't | 276 | 0.0 |
Somatotropin-Releasing Hormone/pharmacology | 29 | 59.0 |
Adolescent | 99 | 0.0 |
Adult | 262 | 0.0 |
Brain Neoplasms/*radiotherapy | 3 | 42.0 |
Cohort Studies | 3 | 0.0 |
Drug Combinations | 8 | 1.0 |
Human Growth Hormone/blood/deficiency/*secretion | 2 | 100.0 |
Insulin/diagnostic use | 5 | 10.0 |
Insulin-Like Growth Factor I/analysis | 21 | 16.0 |
Oligopeptides/*diagnostic use | 5 | 71.0 |
Somatotropin-Releasing Hormone/*diagnostic use | 25 | 75.0 |
Aging/blood | 2 | 3.0 |
Arginine/diagnostic use | 10 | 38.0 |
Body Mass Index | 4 | 0.0 |
Human Growth Hormone/blood/*deficiency | 2 | 40.0 |
Levodopa/diagnostic use | 5 | 19.0 |
Sensitivity and Specificity | 2 | 0.0 |
Sex Characteristics | 14 | 2.0 |
Somatotropin-Releasing Hormone/diagnostic use | 17 | 68.0 |
Stimulation, Chemical | 19 | 3.0 |
Circadian Rhythm | 13 | 5.0 |
Entropy | 6 | 31.0 |
Half-Life | 4 | 0.0 |
Human Growth Hormone/*secretion | 26 | 65.0 |
Animals | 93 | 0.0 |
Dose-Response Relationship, Drug | 30 | 0.0 |
Rats | 48 | 0.0 |
English Abstract | 11 | 0.0 |
Gonadal Steroid Hormones/physiology | 3 | 17.0 |
Hydrocortisone/secretion | 3 | 12.0 |
Hypothalamo-Hypophyseal System/physiopathology | 2 | 5.0 |
Neurosecretory Systems/*physiopathology | 3 | 17.0 |
Obesity/*physiopathology | 4 | 7.0 |
Pituitary-Adrenal System/physiopathology | 2 | 8.0 |
Prolactin/secretion | 9 | 8.0 |
Somatotropin-Releasing Hormone/physiology | 8 | 100.0 |
Human Growth Hormone/blood | 5 | 8.0 |
Somatotropin-Releasing Hormone/blood | 6 | 85.0 |
Circadian Rhythm/physiology | 7 | 12.0 |
Human Growth Hormone/*blood | 12 | 41.0 |
Hypothalamus/*physiopathology | 3 | 17.0 |
Mice | 26 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 78 | 0.0 |
Sleep Stages/*physiology | 3 | 15.0 |
Somatotropin-Releasing Hormone/*physiology | 13 | 92.0 |
Disease Progression | 2 | 0.0 |
Mice, Nude | 7 | 0.0 |
Transplantation, Heterologous | 4 | 0.0 |
Growth Hormone/*deficiency | 7 | 24.0 |
Mutation | 5 | 0.0 |
Receptors, Pituitary Hormone-Regulating Hormone/*genetics | 6 | 37.0 |
Estradiol/*pharmacology | 3 | 1.0 |
Feedback | 8 | 4.0 |
Hormones/*pharmacology | 3 | 6.0 |
Human Growth Hormone/blood/*secretion | 12 | 70.0 |
Oligopeptides/*pharmacology | 19 | 22.0 |
Postmenopause/*physiology | 2 | 8.0 |
Somatotropin-Releasing Hormone/*pharmacology | 63 | 64.0 |
Arginine/administration & dosage/*pharmacology | 4 | 66.0 |
Clonidine/administration & dosage/*pharmacology | 3 | 60.0 |
Drug Interactions | 11 | 0.0 |
Kinetics | 32 | 0.0 |
Levodopa/administration & dosage/*pharmacology | 2 | 40.0 |
Hypothalamus/physiology | 6 | 20.0 |
Pituitary Gland/*physiology | 5 | 20.0 |
Alternative Splicing | 3 | 0.0 |
Immunohistochemistry | 12 | 0.0 |
Somatotropin-Releasing Hormone/*metabolism | 10 | 66.0 |
Amino Acid Sequence/genetics | 2 | 0.0 |
Ligands | 4 | 0.0 |
Molecular Sequence Data | 25 | 0.0 |
*Peptide Hormones | 3 | 50.0 |
Receptors, Cell Surface/metabolism | 4 | 0.0 |
*Receptors, G-Protein-Coupled | 5 | 1.0 |
Tissue Distribution | 4 | 0.0 |
3T3 Cells | 2 | 0.0 |
*Alternative Splicing | 2 | 0.0 |
Cell Division | 6 | 0.0 |
Cyclic AMP/metabolism | 3 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Growth Hormone/metabolism | 2 | 4.0 |
Peptides/chemistry | 2 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Protein Binding | 4 | 0.0 |
Receptors, Neuropeptide/*biosynthesis/*genetics | 2 | 100.0 |
Receptors, Pituitary Hormone-Regulating Hormone/*biosynthesis/*genetics | 2 | 100.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 38 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 10 | 0.0 |
Transfection | 4 | 0.0 |
Vasoactive Intestinal Peptide/pharmacology | 4 | 5.0 |
Acromegaly/*physiopathology | 2 | 22.0 |
Neoplasms, Experimental | 2 | 5.0 |
Signal Transduction | 9 | 0.0 |
Base Sequence | 9 | 0.0 |
Cells, Cultured | 19 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Somatotropin-Releasing Hormone/analysis/*biosynthesis | 2 | 100.0 |
Sheep | 4 | 0.0 |
Time Factors | 44 | 0.0 |
Hypothalamus/*metabolism | 5 | 16.0 |
Infusions, Intravenous | 23 | 3.0 |
Somatotropin-Releasing Hormone/antagonists & | 2 | 100.0 |
Acromegaly/*etiology | 3 | 42.0 |
Insulin-Like Growth Factor I/metabolism | 27 | 13.0 |
Sleep/*drug effects | 5 | 55.0 |
Sleep Stages/drug effects | 3 | 21.0 |
Gonadorelin/*physiology | 2 | 25.0 |
Neurons/physiology | 2 | 1.0 |
Growth Hormone/secretion | 18 | 21.0 |
Somatotropin-Releasing Hormone/*antagonists & inhibitors/pharmacology | 2 | 100.0 |
Area Under Curve | 11 | 2.0 |
Case-Control Studies | 5 | 0.0 |
Obesity/*metabolism | 6 | 8.0 |
Somatotropin-Releasing Hormone/metabolism | 5 | 62.0 |
Acromegaly/*metabolism | 5 | 33.0 |
Protein Isoforms | 2 | 0.0 |
Adenylate Cyclase/metabolism | 2 | 1.0 |
Cell Division/drug effects | 3 | 0.0 |
Cyclic AMP/*metabolism | 3 | 1.0 |
Forskolin/pharmacology | 5 | 1.0 |
Neoplasm Transplantation | 3 | 0.0 |
Radioimmunoassay | 35 | 1.0 |
Somatotropin-Releasing Hormone/*antagonists & inhibitors | 5 | 100.0 |
Age Factors | 6 | 0.0 |
Aging | 2 | 0.0 |
Drug Administration Schedule | 15 | 1.0 |
Growth Hormone/blood/secretion | 4 | 40.0 |
Injections, Intravenous | 27 | 4.0 |
Sex Factors | 5 | 0.0 |
Sleep/*drug effects/*physiology | 2 | 66.0 |
Somatotropin-Releasing Hormone/*administration & dosage | 7 | 87.0 |
Amino Acid Sequence | 19 | 0.0 |
Comparative Study | 58 | 0.0 |
GTP-Binding Proteins/metabolism | 4 | 1.0 |
Swine | 4 | 0.0 |
Growth Hormone/blood/*deficiency/secretion | 2 | 50.0 |
Hydrocortisone/blood | 17 | 4.0 |
Injections, Subcutaneous | 10 | 3.0 |
Insulin-Like Growth Factor I/*metabolism | 8 | 6.0 |
Fatty Acids, Nonesterified/*blood | 5 | 10.0 |
Growth Hormone/*blood | 44 | 24.0 |
Pyrazines/*therapeutic use | 2 | 25.0 |
Statistics, Nonparametric | 3 | 0.0 |
Pituitary Gland/metabolism/physiology | 2 | 66.0 |
Aging/*physiology | 11 | 4.0 |
Atenolol/pharmacology | 2 | 25.0 |
Bromocriptine/pharmacology | 3 | 5.0 |
Somatostatin/*physiology | 6 | 54.0 |
Insulin-Like Growth Factor Binding Protein 1/blood | 2 | 10.0 |
Insulin-Like Growth Factor Binding Protein 3/blood | 5 | 9.0 |
*Periodicity | 2 | 6.0 |
Blood Glucose/analysis | 7 | 1.0 |
Insulin/blood | 8 | 1.0 |
Recombinant Proteins | 4 | 0.0 |
Somatotropin-Releasing Hormone/administration & dosage/*pharmacology | 11 | 64.0 |
Thinness | 2 | 40.0 |
Body Weight | 5 | 0.0 |
*Aging | 5 | 3.0 |
Human Growth Hormone/*physiology/secretion | 3 | 100.0 |
Hypothalamus/*physiology | 2 | 7.0 |
Infant, Newborn | 11 | 0.0 |
Insulin-Like Growth Factor I/*physiology | 3 | 8.0 |
Neurotransmitters/physiology | 4 | 12.0 |
Somatostatin/physiology | 6 | 28.0 |
Somatotropin-Releasing Hormone/*biosynthesis | 3 | 100.0 |
Models, Biological | 2 | 0.0 |
Peptide Fragments/administration & dosage/*pharmacology | 2 | 22.0 |
Placebos | 8 | 3.0 |
Recombinant Proteins/administration & dosage/pharmacology | 2 | 3.0 |
Regression Analysis | 7 | 0.0 |
Somatotropin-Releasing Hormone/administration & dosage/*physiology | 2 | 100.0 |
Cross-Over Studies | 9 | 1.0 |
Double-Blind Method | 7 | 0.0 |
Hypothalamus/drug effects/metabolism | 2 | 18.0 |
Prolactin/blood | 16 | 2.0 |
Somatotropin-Releasing Hormone/*blood | 14 | 100.0 |
Growth Hormone/*physiology | 3 | 11.0 |
Analysis of Variance | 11 | 0.0 |
Drug Synergism | 20 | 1.0 |
Exercise/*physiology | 6 | 1.0 |
Hormones/administration & dosage/*pharmacology | 2 | 66.0 |
Oligopeptides/administration & dosage/*pharmacology | 5 | 83.0 |
Random Allocation | 5 | 1.0 |
Blotting, Western | 2 | 0.0 |
Cell Line | 5 | 0.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
Somatostatin/pharmacology | 7 | 14.0 |
Binding Sites | 2 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
Child, Preschool | 41 | 0.0 |
Infant | 9 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
*Gene Expression | 5 | 0.0 |
Gonadorelin/diagnostic use | 2 | 3.0 |
Protirelin/diagnostic use | 5 | 3.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Receptors, Somatotropin/genetics | 2 | 14.0 |
Peptide Fragments/pharmacology | 5 | 2.0 |
Animals, Newborn | 3 | 0.0 |
Dwarfism/*metabolism | 2 | 50.0 |
Human Growth Hormone/pharmacology | 2 | 11.0 |
Pituitary Gland/*metabolism | 2 | 5.0 |
Rats, Mutant Strains | 2 | 3.0 |
Receptors, Neuropeptide/*genetics | 4 | 19.0 |
Body Height | 7 | 4.0 |
Oligopeptides/adverse effects/*pharmacology | 4 | 66.0 |
Somatotropin-Releasing Hormone/adverse effects/*pharmacology | 3 | 75.0 |
Human Growth Hormone/*metabolism | 5 | 38.0 |
Gonadal Steroid Hormones/blood | 2 | 2.0 |
Hormone Antagonists/pharmacology | 2 | 3.0 |
Clonidine/*diagnostic use | 2 | 66.0 |
Human Growth Hormone/*deficiency/secretion | 3 | 100.0 |
Insulin/*diagnostic use | 2 | 10.0 |
Pyridostigmine Bromide/*diagnostic use | 2 | 100.0 |
Reproducibility of Results | 4 | 0.0 |
Brain Neoplasms/radiotherapy | 3 | 100.0 |
Human Growth Hormone/*blood/*deficiency/secretion | 2 | 100.0 |
Sermorelin/*diagnostic use | 2 | 100.0 |
Electric Conductivity | 2 | 1.0 |
Growth Hormone/blood/deficiency/*secretion | 2 | 50.0 |
Pituitary Gland/*secretion | 6 | 35.0 |
Sequence Alignment | 2 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Anorexia Nervosa/*blood | 2 | 11.0 |
Galanin/*pharmacology | 2 | 40.0 |
Prolactin/*blood | 8 | 1.0 |
Radioligand Assay | 2 | 0.0 |
Receptors, Neuropeptide/*antagonists & inhibitors | 2 | 66.0 |
Receptors, Pituitary Hormone-Regulating Hormone/*antagonists & inhibitors | 2 | 100.0 |
Somatotropin-Releasing Hormone/*analogs & derivatives/pharmacology | 4 | 100.0 |
*Critical Illness | 2 | 10.0 |
Insulin-Like Growth Factor Binding Proteins/metabolism | 2 | 18.0 |
Somatomedins/metabolism | 3 | 10.0 |
Thyrotropin/blood | 13 | 3.0 |
Growth Hormone/blood | 27 | 11.0 |
Calcium/metabolism | 2 | 0.0 |
Growth Hormone/*metabolism/secretion | 2 | 100.0 |
Pituitary Gland/metabolism | 3 | 5.0 |
Rats, Sprague-Dawley | 11 | 0.0 |
Clonidine/diagnostic use | 4 | 57.0 |
Pyridostigmine Bromide/diagnostic use | 4 | 100.0 |
Secretory Rate | 4 | 12.0 |
Chemiluminescent Measurements | 2 | 1.0 |
Octreotide/*pharmacology | 3 | 13.0 |
Dexamethasone/*diagnostic use | 2 | 15.0 |
Growth Hormone/blood/*secretion | 52 | 56.0 |
*Protein Processing, Post-Translational | 2 | 0.0 |
Blood Pressure | 2 | 0.0 |
Corticotropin/deficiency | 2 | 20.0 |
Exercise | 2 | 1.0 |
Human Growth Hormone/*deficiency | 7 | 33.0 |
Hypopituitarism/physiopathology | 2 | 100.0 |
Ventricular Function, Left | 2 | 6.0 |
Cattle | 4 | 0.0 |
Chromatography, Gel | 6 | 0.0 |
Mice, Transgenic | 6 | 0.0 |
Structure-Activity Relationship | 6 | 0.0 |
Aging/*metabolism | 4 | 1.0 |
Body Composition | 5 | 2.0 |
Feedback/physiology | 5 | 20.0 |
Acromegaly/*blood | 4 | 20.0 |
In Situ Hybridization | 3 | 0.0 |
Microscopy, Electron | 3 | 0.0 |
Somatotropin-Releasing Hormone/*drug effects | 3 | 100.0 |
Administration, Intranasal | 8 | 9.0 |
Circadian Rhythm/drug effects | 2 | 14.0 |
Hydrocortisone/*blood | 7 | 4.0 |
Hypothalamo-Hypophyseal System/drug effects | 5 | 29.0 |
Sleep Stages/*drug effects | 2 | 40.0 |
Administration, Oral | 6 | 0.0 |
Bone Density | 2 | 1.0 |
Hypopituitarism/*complications | 4 | 80.0 |
Somatostatin/analysis | 3 | 5.0 |
Computer Simulation | 2 | 0.0 |
Multigene Family | 2 | 0.0 |
Neurosecretory Systems/*physiology | 4 | 14.0 |
Fatty Acids, Nonesterified/blood/*physiology | 2 | 50.0 |
Protirelin/pharmacology | 8 | 6.0 |
Pyrazines/pharmacology | 2 | 18.0 |
Nutrition | 2 | 5.0 |
Weight Loss | 3 | 2.0 |
Human Growth Hormone/secretion | 3 | 13.0 |
Corticotropin/blood | 7 | 4.0 |
Oligopeptides/*therapeutic use | 6 | 35.0 |
Hormone Antagonists/*pharmacology | 2 | 8.0 |
Sermorelin/*analogs & derivatives/pharmacology | 7 | 100.0 |
Endometrial Neoplasms/chemistry/*metabolism | 2 | 100.0 |
Pituitary Gland/drug effects/secretion | 2 | 16.0 |
*Mutation | 3 | 0.0 |
Anthropometry | 2 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Nutritional Status | 2 | 1.0 |
Pakistan | 2 | 5.0 |
Pedigree | 4 | 0.0 |
Phenotype | 2 | 0.0 |
Syndrome | 2 | 0.0 |
Growth Disorders/*blood | 3 | 50.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Immunoradiometric Assay | 8 | 7.0 |
*Sleep | 2 | 8.0 |
Pituitary Gland/drug effects | 5 | 35.0 |
Aging/physiology | 4 | 2.0 |
Hypothalamus/*secretion | 3 | 42.0 |
Sleep, REM/*physiology | 2 | 20.0 |
Human Growth Hormone/*blood/secretion | 3 | 75.0 |
Adenoma/pathology/secretion | 2 | 100.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Pituitary Neoplasms/pathology/secretion | 2 | 100.0 |
Growth Hormone/*secretion | 42 | 35.0 |
Peptides/*pharmacology | 2 | 0.0 |
Pituitary Gland/*drug effects/secretion | 5 | 55.0 |
Somatotropin-Releasing Hormone/blood/*secretion | 7 | 100.0 |
Growth Hormone/drug effects/*secretion | 2 | 100.0 |
Pituitary Gland, Anterior/*drug effects/secretion | 2 | 33.0 |
Osmolar Concentration | 6 | 0.0 |
Pulsatile Flow | 4 | 9.0 |
Gonadorelin/*pharmacology | 2 | 5.0 |
Growth Hormone/*metabolism | 10 | 19.0 |
Hormones/*diagnostic use | 2 | 66.0 |
Secretory Rate/drug effects | 14 | 16.0 |
Estradiol/blood | 5 | 0.0 |
Recombinant Proteins/pharmacology | 5 | 0.0 |
Testosterone/blood | 3 | 0.0 |
Peptide Fragments/*pharmacology | 6 | 3.0 |
Gene Expression | 6 | 0.0 |
Hypothalamus/*drug effects/secretion | 2 | 28.0 |
Growth Substances/*pharmacology | 4 | 1.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Hypothalamus/drug effects/secretion | 3 | 50.0 |
Somatostatin/secretion | 4 | 36.0 |
Secretory Rate/physiology | 2 | 25.0 |
Prolactin/blood/*secretion | 3 | 1.0 |
Somatostatin/*pharmacology | 6 | 12.0 |
Cholinesterase Inhibitors/*pharmacology | 4 | 6.0 |
Oligopeptides/*administration & dosage/pharmacology | 2 | 100.0 |
Pyridostigmine Bromide/*pharmacology | 17 | 80.0 |
Growth Substances/pharmacology | 2 | 1.0 |
Somatotropin-Releasing Hormone/*genetics | 3 | 75.0 |
Follow-Up Studies | 3 | 0.0 |
Pituitary Gland, Anterior/cytology/*metabolism | 3 | 75.0 |
*Sulfonamides | 2 | 3.0 |
Parasympathomimetics/*therapeutic use | 2 | 100.0 |
Human Growth Hormone/blood/secretion | 2 | 40.0 |
Periodicity | 4 | 8.0 |
Insulin-Like Growth Factor I/*analysis | 2 | 3.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Antilipemic Agents/*pharmacology | 4 | 10.0 |
Pyrazines/*pharmacology | 4 | 12.0 |
Single-Blind Method | 3 | 1.0 |
Hyperplasia | 7 | 1.0 |
Pituitary Gland/*pathology | 3 | 17.0 |
Electroencephalography | 2 | 0.0 |
Obesity/*blood | 3 | 3.0 |
Somatotropin-Releasing Hormone/administration & dosage | 3 | 100.0 |
Insulin-Like Growth Factor I/analysis/metabolism | 2 | 25.0 |
Arginine/*pharmacology | 11 | 36.0 |
Levodopa/*pharmacology | 5 | 29.0 |
Somatotropin-Releasing Hormone/*blood/secretion | 4 | 100.0 |
Gonadorelin/blood | 2 | 33.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Somatostatin/*metabolism | 4 | 17.0 |
Somatotropin-Releasing Hormone/genetics/*metabolism | 2 | 100.0 |
Somatotropin-Releasing Hormone/*therapeutic use | 6 | 54.0 |
Cholinergic Agents/pharmacology | 2 | 25.0 |
Growth Hormone/pharmacology | 2 | 5.0 |
Hypothalamus/metabolism | 4 | 8.0 |
Pyridostigmine Bromide/pharmacology | 10 | 71.0 |
Somatostatin/metabolism | 8 | 16.0 |
Pituitary Gland/physiology | 3 | 11.0 |
Hypothalamo-Hypophyseal System/*physiopathology | 3 | 5.0 |
Somatotropin-Releasing Hormone/*antagonists & inhibitors/physiology | 2 | 100.0 |
Body Weight/drug effects | 3 | 1.0 |
Blood Glucose/metabolism | 8 | 1.0 |
Lipolysis/drug effects | 2 | 6.0 |
Obesity/blood/*physiopathology | 4 | 25.0 |
Adenoma/*physiopathology | 2 | 22.0 |
Evaluation Studies | 2 | 0.0 |
Growth Hormone/*deficiency/secretion | 6 | 85.0 |
Hypoglycemia/*physiopathology | 2 | 22.0 |
Pituitary Neoplasms/*physiopathology | 2 | 33.0 |
Somatotropin-Releasing Hormone/administration & dosage/*diagnostic use | 5 | 100.0 |
Growth/*physiology | 2 | 14.0 |
Insulin-Like Growth Factor I/physiology | 2 | 6.0 |
Puberty/*physiology | 2 | 10.0 |
*Circadian Rhythm | 4 | 1.0 |
Thyrotropin/secretion | 4 | 10.0 |
Clonidine/*pharmacology | 5 | 21.0 |
Oligopeptides/administration & dosage/*diagnostic use | 2 | 100.0 |
Somatotropin-Releasing Hormone/*administration & dosage/pharmacology | 6 | 85.0 |
Insulin/*blood | 2 | 1.0 |
Clonidine/pharmacology | 4 | 26.0 |
Hypoglycemia/metabolism | 2 | 50.0 |
Levodopa/pharmacology | 6 | 22.0 |
*Hypophysectomy | 2 | 16.0 |
Somatotropin-Releasing Hormone | 2 | 66.0 |
Growth Hormone/blood/*deficiency | 6 | 66.0 |
Blotting, Northern | 4 | 0.0 |
Placenta/*chemistry | 2 | 5.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Corticotropin-Releasing Hormone/administration & dosage/*pharmacology | 2 | 33.0 |
Hormones/pharmacology | 2 | 4.0 |
Drug Therapy, Combination | 2 | 0.0 |
Acromegaly/etiology | 3 | 42.0 |
Dexamethasone/pharmacology | 3 | 0.0 |
Glucocorticoids/*physiology | 2 | 11.0 |
Hypothalamo-Hypophyseal System/physiology | 3 | 10.0 |
Propranolol/pharmacology | 2 | 4.0 |
Adenoma/*metabolism | 2 | 3.0 |
Culture Techniques | 3 | 0.0 |
DNA Primers | 3 | 0.0 |
Puberty/*metabolism | 2 | 28.0 |
Galanin | 6 | 15.0 |
Growth Disorders/*drug therapy/physiopathology | 2 | 66.0 |
Insulin-Like Growth Factor I/secretion | 3 | 75.0 |
Peptides/administration & dosage/*pharmacology | 3 | 33.0 |
Pituitary Gland/secretion | 3 | 25.0 |
Corticotropin/*blood | 2 | 3.0 |
Electroencephalography/*drug effects | 3 | 14.0 |
Sleep Stages | 2 | 20.0 |
Pirenzepine/*pharmacology | 2 | 66.0 |
Anorexia Nervosa/*physiopathology | 2 | 20.0 |
Octreotide/*therapeutic use | 3 | 8.0 |
Immune Sera | 2 | 0.0 |
Somatotropin-Releasing Hormone/administration & dosage/adverse | 2 | 100.0 |
Cranial Irradiation/*adverse effects | 2 | 50.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
Somatotropin-Releasing Hormone/*biosynthesis/pharmacology | 2 | 100.0 |
Somatotropin-Releasing Hormone/diagnostic use/secretion | 2 | 100.0 |
Hypothalamo-Hypophyseal System/drug effects/physiology | 2 | 22.0 |
Somatotropin-Releasing Hormone/blood/*pharmacology | 2 | 100.0 |
Somatotropin-Releasing Hormone/genetics/*physiology | 2 | 66.0 |
Levodopa/*diagnostic use | 3 | 33.0 |
Pituitary Function Tests | 5 | 16.0 |
Corticotropin-Releasing Hormone/*pharmacology | 2 | 8.0 |
Erythropoietin/*therapeutic use | 2 | 2.0 |
*Renal Dialysis | 3 | 0.0 |
Bromocriptine/therapeutic use | 2 | 2.0 |
Hormones, Ectopic/blood/*secretion | 2 | 100.0 |
Body Constitution | 2 | 1.0 |
Growth Hormone/deficiency/*secretion | 5 | 100.0 |
Puberty | 2 | 2.0 |
Insulin-Like Growth Factor I/biosynthesis | 2 | 18.0 |
Somatotropin-Releasing Hormone/administration & dosage/pharmacology | 3 | 100.0 |
Molecular Weight | 2 | 0.0 |
Arginine/administration & dosage/*diagnostic use | 2 | 100.0 |
Hypothalamus/physiopathology | 3 | 18.0 |
Corticotropin/secretion | 2 | 3.0 |
Neurotransmitters/*physiology | 2 | 6.0 |
Pituitary Gland/drug effects/*secretion | 2 | 16.0 |
Age Determination by Skeleton | 5 | 25.0 |
Body Height/drug effects | 5 | 23.0 |
Growth Disorders/blood/diagnosis/*drug therapy/etiology | 3 | 100.0 |
Infusions, Parenteral | 8 | 5.0 |
Sermorelin/administration & dosage/blood/pharmacology/*therapeutic use | 2 | 100.0 |
Sermorelin/*administration & dosage/blood/pharmacology/therapeutic use | 2 | 100.0 |
Leg/growth & development | 2 | 100.0 |
Follicle Stimulating Hormone/blood | 4 | 0.0 |
Prospective Studies | 3 | 0.0 |
Somatostatin/*secretion | 5 | 62.0 |
Growth Hormone/metabolism/*physiology | 2 | 100.0 |
Exercise Test | 2 | 0.0 |
Linear Models | 2 | 0.0 |
Gonadorelin/*metabolism | 2 | 18.0 |
Neurons/*metabolism | 2 | 0.0 |
Prolactin/metabolism | 2 | 3.0 |
Dogs | 2 | 0.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
Somatostatin/blood | 2 | 8.0 |
Hypothalamus/drug effects | 3 | 23.0 |
Somatotropin-Releasing Hormone/administration & | 2 | 100.0 |
Growth Disorders/*drug therapy | 3 | 37.0 |
Parasympathetic Nervous System/*physiology | 2 | 14.0 |
Glucose/administration & dosage/*pharmacology | 2 | 16.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Rats, Inbred Strains | 9 | 1.0 |
Depression, Chemical | 3 | 1.0 |
Growth Hormone/antagonists & inhibitors/*secretion | 2 | 50.0 |
Receptors, Muscarinic/*drug effects/physiology | 2 | 100.0 |
Somatotropin-Releasing Hormone/antagonists & inhibitors/*pharmacology | 4 | 80.0 |
Autoradiography | 2 | 0.0 |
Eating | 2 | 1.0 |
Insulin/blood/*pharmacology | 2 | 10.0 |
Pituitary Gland/chemistry | 2 | 9.0 |
Somatostatin/*blood | 5 | 27.0 |
*Puberty | 2 | 8.0 |
Somatotropin-Releasing Hormone/diagnostic use/*pharmacology | 2 | 66.0 |
Peptide Fragments/*therapeutic use | 3 | 17.0 |
Pituitary Neoplasms/*secretion | 2 | 4.0 |
Pyridostigmine Bromide/administration & dosage/*pharmacology | 2 | 100.0 |
Pituitary Gland, Anterior/drug effects/*secretion | 3 | 30.0 |
Verapamil/pharmacology | 2 | 2.0 |
Acromegaly/etiology/*metabolism | 2 | 100.0 |
Somatostatin/*analysis | 3 | 16.0 |
Somatotropin-Releasing Hormone/*analysis | 6 | 85.0 |
Hyperthyroidism/blood/*physiopathology | 2 | 50.0 |
Sermorelin | 8 | 88.0 |
Hypothalamus/drug effects/*physiology | 2 | 28.0 |
Somatotropin-Releasing Hormone/*diagnostic use/pharmacology | 2 | 100.0 |
*Sex Characteristics | 2 | 1.0 |
Insulin/pharmacology | 5 | 1.0 |
Growth Hormone/*blood/secretion | 7 | 63.0 |
Calcitonin/*pharmacology | 2 | 11.0 |
Corticotropin-Releasing Hormone/pharmacology | 4 | 11.0 |
Insulin/*pharmacology | 3 | 1.0 |
Insulin-Like Growth Factor I/*pharmacology | 3 | 2.0 |
Thyrotropin/*metabolism | 2 | 9.0 |
Gonadorelin/*genetics | 2 | 25.0 |
Hypophysectomy | 2 | 3.0 |
Luteinizing Hormone/blood | 4 | 0.0 |
Fatty Acids, Nonesterified/blood | 2 | 1.0 |
Hypoglycemia/chemically induced/*metabolism | 2 | 33.0 |
Protirelin/administration & dosage | 3 | 37.0 |
Pituitary Gland/drug effects/physiology | 2 | 33.0 |
Pregnancy/*blood | 2 | 1.0 |
Diabetes Mellitus, Type 1/*blood | 2 | 1.0 |
*Food | 2 | 2.0 |
Acute Disease | 2 | 0.0 |
Hypoglycemia/blood/*chemically induced | 2 | 66.0 |
Somatotropin-Releasing Hormone/*blood/physiology | 2 | 100.0 |
Circadian Rhythm/*physiology | 2 | 2.0 |
Gonadorelin/pharmacology | 2 | 4.0 |
Pituitary Hormone-Releasing Hormones/*pharmacology | 2 | 15.0 |
Pituitary Hormones, Anterior/metabolism | 2 | 50.0 |
Neurosecretory Systems/metabolism | 2 | 14.0 |
Corticotropin-Releasing Hormone/blood | 2 | 12.0 |
Insulin-Like Growth Factor I/blood | 6 | 35.0 |
Glucose/pharmacology | 2 | 1.0 |
Growth Disorders/blood/*drug therapy | 4 | 66.0 |
Somatotropin-Releasing Hormone/administration & dosage/*therapeutic use | 4 | 100.0 |
Peptide Fragments/*administration & dosage | 2 | 40.0 |
Pituitary Gland, Anterior/*secretion | 2 | 13.0 |
Growth Hormone/*deficiency/therapeutic use | 2 | 40.0 |
Peptide Fragments/*diagnostic use | 2 | 40.0 |
Pituitary Gland, Anterior/secretion | 2 | 20.0 |
Insulin-Like Growth Factor I/*blood | 3 | 30.0 |
Somatomedins/*blood | 3 | 18.0 |
In Vitro | 4 | 0.0 |
Gestational Age | 2 | 0.0 |
Octreotide | 2 | 16.0 |
Somatostatin/*analogs & derivatives/therapeutic use | 2 | 18.0 |
Acromegaly/metabolism | 3 | 23.0 |
Dwarfism, Pituitary/blood | 2 | 50.0 |
Dwarfism, Pituitary/*physiopathology | 2 | 100.0 |
Pancreatic Neoplasms/*secretion | 2 | 20.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Growth Disorders/*blood/drug therapy | 2 | 66.0 |
Peptide Hormones/*metabolism | 2 | 50.0 |
Somatotropin-Releasing Hormone/*diagnostic use/therapeutic use | 2 | 100.0 |
Amino Acids/pharmacology | 2 | 10.0 |
Histocytochemistry | 2 | 0.0 |
Insulin-Like Growth Factor I | 2 | 22.0 |
Somatomedins/blood | 2 | 40.0 |
Arginine/*diagnostic use | 2 | 25.0 |
Hypopituitarism/*diagnosis | 2 | 66.0 |
